Overview

The increasing value of emerging markets to the pharmaceutical industry is widely acknowledged. However, in many cases these markets will be ones in which local custom and practice may include the use of facilitation payments or the conferring of other benefits that could be regarded as bribery under the Bribery Act 2010.

The Act establishes four types of offence. The first three offences can be committed by either a company or an individual, while the fourth offence can only be committed by a company: bribing another person; being bribed; bribing a foreign public official; and failure by a commercial organisation to prevent bribery (the corporate offence).

Taylor Wessing’s report outlines the impact the Bribery Act is likely to have on the pharmaceutical industry.

To read more, click View Briefing.